Opinion
FDA amended EUA for COVID bivalent mRNA technology booster (April 18th) (Pfzier-BioNTech & Moderna for original & BA4/BA5 clades); then CDC’s ACIP advisory group met April 19th, 2023
VRBPAC (Jan 26th 2023); for this ‘simplified’ approach Dr. Wiseman below outlines the FAILURE & risk of the FDA & CDC decisions given no supporting data, omission of VAERS data on stroke signals
This article was republished from the author’s Substack.
Dr. David Weisman (excellent scholarship) is the lead scientist here:
ACIP April 19 2023: Bivalent primary series dosing with no directly supportive data and in the face of ever more resistant variants. Ischemic stroke signal in VAERS ignored. Written remarks CDC-2023-0028
This DailyClout article is the writer’s opinion.
One of our country’s most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE.
One of our country’s most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE.